• Room 01.058 - Pharmacy & MCI Block 98 MBC Site

    United Kingdom

Accepting PhD Students

Willing to speak to media

If you made any changes in Pure these will be visible here soon.

Personal profile


Professor Gavin Andrews is chair of pharmaceutical engineering and has research interests in development of novel orally administered solid dosage forms and biomaterials. This involves the use of engineering techniques for controlled/targeted delivery within the gastrointestinal tract and solubility enhancement of poorly soluble therapeutics and the use of multi-layer extrusion technology for manufacture of biomaterials and complex oral dosage forms. Professor Andrews has secured funding from a wide range of sources, including EPSRC, EU, The Wellcome Trust, SFI, NSF, DEL and The Royal Society (https://royalsociety.org/grants/case-studies/gavin-andrews/). His research, which has a significant industrial focus, has been extensively sponsored by major multinational pharmaceutical companies and he has played a central role in technology transfer between academia and industry through funding from Innovate UK, Enterprise Ireland and Invest Northern Ireland. Professor Andrews sits on the Editorial Advisory Boards of Drug Development & Industrial Pharmacy, Journal of Pharmacy & Pharmacology and Journal of Pharmaceutical Sciences. He has published his research widely in internationally peer-reviewed pharmaceutics journals and has been invited to present at leading national and international conferences. He has formed strong collaborative links with researchers in the UK, Europe and the United States, held a Royal Society Industry Fellowship with Astra-Zeneca from 2009-2014, is the current President of the UK & Ireland Controlled Release Society (www.ukircs.org) and is a member of the Academy of Pharmaceutical Sciences Expert Subject Group on Materials Science.

Professor Andrews’ leads a dynamic research group that has its focus in pharmaceutical engineering with a specific emphasis on secondary processing. Research sits at the interface between pharmaceutical sciences and chemical engineering with the aim of challenging the traditional methods commonly used to manufacture oral dosage forms and drug delivery platforms. The group have a strong interest in emerging pharmaceutical manufacturing technologies and in understanding their inherent advantages and disadvantages. Ultimately, the group aims to design and manufacture both oral drug delivery and biomaterial products via a quality-by-design rather than quality-by analysis approach. To date, focus has been on hot melt extrusion and more recently injection moulding. Furthermore, we are interested in novel ways of producing intricate and personalised dosage forms (Fixed Dose Combinations). Our general aim is to better understand the capabilities of each process and to build an understanding of the interrelation between formulation and processing factors and the impact these have upon end product performance. Interestingly, over the last 10 years there has been a significant drive towards continuous processing. HME and IM may be used for continuous production of high quality drug delivery products in a single step whilst also permitting real time characterisation using process analytical technologies. Recent work in this area, included in The Royal Society Trustees’ Report (https://royalsociety.org/~/media/about-us/reporting/2014-17-9-trustees-report.pdf?la=en-GB), involves the manufacture of solid dispersions and co-crystals to improve the dissolution rate of poorly water-soluble drugs, one of the major challenges in dosage form development. We have also received considerable funding from Science Foundation Ireland and The Department for Employment and Learning (~£1M) to develop fixed dose combination products along with colleagues at Trinity College Dublin and Eli Lilly (USA). Moreover, the group has strong international links with major multinational pharmaceutical companies and universities (e.g., Eli Lilly, Astra Zeneca, Capsugel, Trinity College Dublin, University of Limerick, Purdue University, Rutgers University, Ghent University, CSOPS, SSPC) and has recently received $1.4M for a US-Ireland partnership to develop continuous manufacturing for nano-based drug products.

Fingerprint Dive into the research topics where Gavin Andrews is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 6 Similar Profiles
Polymers Medicine & Life Sciences
Pharmaceutical Preparations Medicine & Life Sciences
Solubility Medicine & Life Sciences
Dosage Forms Medicine & Life Sciences
Temperature Medicine & Life Sciences
Celecoxib Medicine & Life Sciences
Granulation Chemical Compounds
Povidone Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2006 2018

Research Output 2000 2019

Analysis of variance (ANOVA)
Pharmaceutical Preparations

Co-extruded Fixed Dose Combination Products with Enabled Properties for the Treatment of Cardiovascular Diseases

Almajaan, A., Li, S., Gilvary, G. C., Senta Loys, Z., Tian, Y., Kelleher, J., Healy, A-M., Jones, D. & Andrews, G., 03 Apr 2019.

Research output: Contribution to conferencePaper

Open Access
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cardiovascular Diseases

Fixed Dose Combination Formulations: Multi-Layered Platforms Designed for the Management of Cardiovascular Disease

Andrews, G. P., Li, S., Almajaan, A., Yu, T., Martini, L., Healy, A. M. & Jones, D. S., 31 Jan 2019, In : Molecular Pharmaceutics.

Research output: Contribution to journalArticle

Cardiovascular Diseases
Hydroxymethylglutaryl-CoA Reductase Inhibitors

Solvent and water free lipid-based nanoparticles and their methods of manufacture

Andrews, G., Jones, D. & Tian, Y., Jan 2019, Patent No. United Kingdom 1900389.6

Research output: Patent

Quality Control
Raman Spectrum Analysis
High Pressure Liquid Chromatography

Activities 2006 2018

External PhD Examiner King's College London

Gavin Andrews (Examiner)

Activity: Examination typesPhD external examination

External PhD Examiner UEA

Gavin Andrews (Examiner)

Activity: Examination typesPhD external examination

External PhD Examiner Nottingham University

Gavin Andrews (Examiner)

Activity: Examination typesPhD external examination

Development of HME eLearning course for AAPS

Justin Tian (Contributor), Gavin Andrews (Contributor)
Sep 2017Oct 2017

Activity: Consultancy typesContribution to the work of national or international committees and working groups

PEARRL Annual Meeting

Gavin Andrews (Invited speaker)
19 Jun 2017

Activity: Participating in or organising an event typesParticipation in conference

Press / Media

SSPC Feature of US-Ireland Partnership Funding Award

Gavin Andrews


1 media contribution

Press/Media: Research

Research feature in Royal Society Trustees' Report

Gavin Andrews


1 media contribution

Press/Media: Research


Characterisation of Drug Loaded Insoluble Polymeric Matrices Prepared by Hot Melt Extrusion Technology for Drug Delivery Applications

Author: Caldwell, D., Jun 2012

Supervisor: Andrews, G. (Supervisor) & Jones, D. (Supervisor)

Student thesis: Doctoral ThesisDoctor of Philosophy


Physicochemical characterization of solid dispersions prepared using hot-melt extrusion technology

Author: Abu Diak, O., Sep 2009

Supervisor: Andrews, G. (Supervisor) & Jones, D. (Supervisor)

Student thesis: Doctoral ThesisDoctor of Philosophy